A precision-oncology company developing small-molecule therapies to restore function of mutant forms of the tumor suppressor protein p53. The lead candidate is rezatapopt (PC14586), which is designed ...

German science and technology group Merck KGaA (MRK: DE) has upgraded its full-year outlook after a second quarter in which its laboratory and semiconductor materials businesses more than covered a ...

UK-based clinical-stage pharma company Actimed Therapeutics today revealed that it has regained exclusive global rights to the anabolic-catabolic transforming agent (ACTA) S-oxprenolol from US biotech ...

US pharma major Eli Lilly (NYSE: LLY) reported second-quarter 2026 revenue of $23 billion, up 48% year-on-year from $15.6 billion in the second quarter of 2025 and well ahead of Wall Street forecasts ...

Adneuris Therapeutics, a wholly-owned subsidiary of Tris Pharma advancing a new kind of pain medicine, announced that it has ...

There are "no discussions" ongoing between AstraZeneca and Bristol Myers Squibb over a potential deal, a senior source close to the matter told Reuters on Wednesday, quashing the prospect of a mooted ...

Cambridge, USA-based mRNA vaccines company Moderna announced that the US Food and Drug Administration (FDA) has approved ...

Sidera Bio is headquartered in Copenhagen, Denmark, with a U.S. presence in Cambridge, Massachusetts. The company operates across the European and U.S. biotech ecosystems and is focused on developing ...

A clinical-stage immunology company based in the United States, operating within the Boston biotechnology ecosystem. Poplar Therapeutics was previously known as Phylaxis Bioscience and was ...

A UK-headquartered clinical-stage biopharmaceutical company developing once-weekly oral GLP-1 and amylin analogs for obesity and cardiometabolic disorders, backed by a $411 million Series A. A ...

A clinical-stage biotechnology company focused on targeted therapies for severe autoimmune diseases. The company’s development strategy is centered on brepocitinib, an oral dual TYK2/JAK1 inhibitor ...

A European antibody-drug conjugate developer acquired by Eli Lilly in August 2023 for up to $600 million, whose lead Nectin-4 ADC, ETx-22, was subsequently deprioritized inside Lilly's dual-track ...